BFO
IBB icon

Boston Family Office’s iShares Biotechnology ETF IBB Stock Holding History

Boston Family Office’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,389
Closed -$230K – 251
2018
Q4 		$230K Buy
+2,389
New +$254K 0.03% 233

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Boston Family Office's IBB Position: Q1 2019 in Review

Boston Family Office sold out of iShares Biotechnology ETF (IBB) in Q1 2019, closing a stake of 2,389 shares — an estimated $230K sold.

Boston Family Office first reported a position in IBB in Q4 2018 and held it in 1 quarter. The position peaked at $230K in Q4 2018. 670 funds tracked by Wall St. Rank hold IBB as of Q1 2019.

  • Boston Family Office reported no remaining iShares Biotechnology ETF position as of Q1 2019 after selling out during the quarter.
  • Boston Family Office sold 2,389 iShares Biotechnology ETF shares in Q1 2019, an estimated $230K.
  • Boston Family Office first reported a position in iShares Biotechnology ETF in Q4 2018 and held it in 1 quarter.
  • Boston Family Office's iShares Biotechnology ETF position peaked at $230K in Q4 2018.
  • 670 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2019.

Based on Boston Family Office's 13F filing for Q1 2019, filed 9 May 2019.